UK markets closed

LENSAR, Inc. (LNSR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.2600+0.0800 (+2.52%)
At close: 04:00PM EDT
3.3200 +0.06 (+1.84%)
After hours: 06:30PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.1800
Open3.3000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range3.1800 - 3.3750
52-week range1.8000 - 5.3000
Volume15,145
Avg. volume44,500
Market cap37.148M
Beta (5Y monthly)0.47
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

    ORLANDO, Fla., May 02, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, May 9, 2024 to discuss the financial results and recent corporate highlights.

  • Business Wire

    LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ORLANDO, Fla., May 01, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock. The options were granted as of May 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5

  • Business Wire

    LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

    ORLANDO, Fla., March 04, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2023 and provided an update on key operational initiatives.